A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53233

language	eng
Author	Uchio, Yuji Enomoto Hiroyuki Bio-Medicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan Alev Levent Bio-Medicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan Kato Yuki Clinical Development Department, Shionogi & Co., Ltd., Osaka, Japan Ishihara Hiroyuki Clinical Development Department, Shionogi & Co., Ltd., Osaka, Japan Tsuji Toshinaga Medical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan Ochiai Toshimitsu Biostatistics Department, Shionogi & Co., Ltd., Osaka, Japan Konno Shinichi Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan
Subject	double-blind; randomized; placebo-controlled trial; duloxetine; osteoarthritis
Journal Title	JOURNAL OF PAIN RESEARCH
Volume	11
Start Page	809
End Page	821
ISSN	1178-7090
Published Date	2018
DOI	10.2147/JPR.S164128
PubMed ID	29713194
Publisher	DOVE MEDICAL PRESS LTD
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	The authors thank all clinical investigators and patients for their participation in the study. The authors thank Marion Barnett and Nicholas Smith of Edanz Medical Writing for providing medical writing support, which was funded by Shionogi & Co., Ltd. Editing of the final manuscript was provided by Serina Stretton of ProScribe-Envision Pharma Group and funded by Shionogi & Co., Ltd.; This work was supported by Shionogi & Co., Ltd., Eli Lilly Japan K. K., and Eli Lilly and Company. Shionogi & Co., Ltd., Eli Lilly Japan K. K., and Eli Lilly and Company contributed to study design, data analysis, and writing of the manuscript.